5:31 AM
 | 
Apr 12, 2018
 |  BC Extra  |  Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on subgroup data from the trial. Adynxx plans to start a Phase III trial of brivoligide in early 2019 to treat postsurgical pain in patients...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >